SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Profit Outlook
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
SpringWorks Gains After Cancelling From Investor Conference
Express News | Merck KGaA CEO Says We Refer to Our Previous Statement on SpringWorks, When Asked About Any Progress of Talks
Investors Push SpringWorks Therapeutics (NASDAQ:SWTX) 4.9% Lower This Week, Company's Increasing Losses Might Be to Blame
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Springworks Therapeutics (SWTX)
10 Health Care Stocks Whale Activity In Today's Session
J.P. Morgan Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $70
J.P. Morgan Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Insider Sold Shares Worth $2,866,534, According to a Recent SEC Filing
Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts
Why SpringWorks Therapeutics, Inc. (SWTX) Is the Best Performing Pharma Stock So Far in 2025
Guggenheim Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Cuts Target Price to $77
SpringWorks Therapeutics Analyst Ratings
H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $74
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $63 to $87
Express News | SpringWorks Therapeutics Inc : Guggenheim Cuts Target Price to $77 From $78
Here's Why We're Not At All Concerned With SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation